| Anixa Biosciences is an early stage biotechnology company. Co.'s subsidiary, Anixa Diagnostics Corporation, develop Cchek, a platform for non-invasive blood tests for the early detection of cancer. Co.'s Cchek cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence, and quantity of certain immune cells that exist in and around a tumor and that can be found in the blood stream. Co.'s other subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. Co. is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling. We show 3 historical shares outstanding datapoints in our coverage of ANIX's shares outstanding history.|
Understanding the changing numbers of ANIX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ANIX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ANIX by allowing them to research ANIX shares outstanding history
as well as any other stock in our coverage universe.